Herantis Pharma

Herantis' share price has fallen in recent weeks, and the valuation has become attractive again.

Herantis' Phase 1b clinical trial achieved all its objectives. The most significant outcomes were good tolerability and safetyof HER-096, as well as the drug candidate's anticipated pharmacokinetics.

Herantis management will host a webcast about phase 1b data readout on October 8th, at 13:00 EEST.

Herantis announced the final results of the clinical Phase Ib trial of its Parkinson's disease drug candidate HER-096. The study met all its primary and secondary objectives.

Herantis' early part of the year proceeded as expected and on schedule. The ongoing clinical trial is in its final stages, and key results are expected by mid-October.

Herantis' Phase Ib clinical trial in Parkinson's disease with the investigational drug HER-096 is nearing completion, and the last patient visit has already taken place.

Herantis initiated a Phase Ib clinical study in Parkinson's disease with the investigational drug HER-096 in H2 last year. The first results are expected to be completed in the coming weeks, and the full study data will be released by the end of the year.